Cytokinetics, Inc. (CYTK: Quote) announced encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
Jeremy Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, concluded that CK-2017357 appeared to be safe and well-tolerated dosed daily at 125 mg, 250 mg, and 375 for two weeks, and that encouraging trends were observed in the ALSFRS-R and MVV. As expected, plasma concentrations of CK-2017357 were unaffected by co-administration with riluzole, while riluzole levels increased during co-administration with CK-2017357.
Adverse events and clinical assessments during treatment with CK-2017357 appeared similar, with or without co-administration of riluzole at the reduced dose of 50 mg daily. Dizziness, the most commonly reported adverse event, was mostly mild and generally began and resolved early after initiating treatment.
Click here to receive FREE breaking news email alerts for Cytokinetics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com